Evidence map›Paper›PMID 32511369›Full record

ArticlebioRxiv : the preprint server for biology2020

A Modular Microarray Imaging System for Highly Specific COVID-19 Antibody Testing.

Per Niklas Hedde, Timothy J Abram, Aarti Jain, Rie Nakajima, Rafael Ramiro de Assis, Trevor Pearce, Algis Jasinskas, Melody N Toosky, Saahir Khan, Philip L Felgner and 2 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Per Niklas HeddeDepartment of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, USA.
Timothy J AbramVelox Biosystems, Irvine, CA, USA.
Aarti JainDepartment of Physiology and Biophysics, University of California, Irvine, Irvine, CA, USA.
Rie NakajimaDepartment of Physiology and Biophysics, University of California, Irvine, Irvine, CA, USA.
Rafael Ramiro de AssisDepartment of Physiology and Biophysics, University of California, Irvine, Irvine, CA, USA.
Trevor PearceDepartment of Biomedical Engineering, University of California, Irvine, Irvine, CA, USA.
Algis JasinskasDepartment of Physiology and Biophysics, University of California, Irvine, Irvine, CA, USA.
Melody N TooskyVelox Biosystems, Irvine, CA, USA.
Saahir KhanDivision of Infectious Diseases, Department of Medicine, University of California Irvine Health, Orange, CA, USA.
Philip L FelgnerDepartment of Physiology and Biophysics, University of California, Irvine, Irvine, CA, USA.
Enrico GrattonDepartment of Biomedical Engineering, University of California, Irvine, Irvine, CA, USA.
Weian ZhaoDepartment of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, USA.
University of California, Irvine · USFluor (United States) · US

Funding

TRD4: Phasor analysisP41GM103540 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI GRATTON, ENRICO · 2012 to 2020
$12.5M
Institutional Career Development CoreKL2TR001416 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI CAIOZZO, VINCENT JAMES, DEMETRIOU, MICHAEL · 2015 to 2023
$5.6M
Integrated Comprehensive Droplet Digital Detection (IC 3D) system for rapid detection of bacteria andantimicrobial resistanceR01AI117061 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI ZHAO, WEIAN · 2015 to 2019
$5.1M
NCATS NIH HHS KL2 TR001416NIAID NIH HHS R01 AI117061NIGMS NIH HHS P41 GM103540
6 · The paper itself

Abstract

To detect the presence of antibodies in blood against SARS-CoV-2 in a highly sensitive and specific manner, here we describe a robust, inexpensive ($200), 3D-printable portable imaging platform (TinyArray imager) that can be deployed immediately in areas with minimal infrastructure to read coronavirus antigen microarrays (CoVAMs) that contain a panel of antigens from SARS-CoV-2, SARS-1, MERS, and other respiratory viruses. Application includes basic laboratories and makeshift field clinics where a few drops of blood from a finger prick could be rapidly tested in parallel for the presence of antibodies to SARS-CoV-2 with a test turnaround time of only 2-4 h. To evaluate our imaging device, we probed and imaged coronavirus microarrays with COVID-19-positive and negative sera and achieved a performance on par with a commercial microarray reader 100x more expensive than our imaging device. This work will enable large scale serosurveillance, which can play an important role in the months and years to come to implement efficient containment and mitigation measures, as well as help develop therapeutics and vaccines to treat and prevent the spread of COVID-19.

Identifiers

PMID32511369
PMCPMC7263497
OpenAlexW3028137776

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.